Accueil   Appels à projets   IMI2 - Call 21 Development of therapeutics and diagnostics combatting coronavirus infections

IMI2 – Call 21 Development of therapeutics and diagnostics combatting coronavirus infections

Les grandes lignes de l'appel à projets

Type de l'appel : Collaboratif

Date d'ouverture : 28 Février 2020

Date de clôture : 31 Mars 2020

Dimension : Europe

Financement :

Thématique(s) médicale(s) : Maladies infectieuses - Infectiologie, Santé humaine, Technologies Médicales

Secteur(s) industriel(s) : Diagnostic in vitro, Médicaments et vaccin à usage humain ou animal

IMI (Innovative Medicines Initiative) is a public private partnership between pharma industry members of the EFPIA (European Federation of Pharmaceutical Industries and Associations) and the European Union.

The aim is to support financially the European research collaboration in the field of innovative medicines to reinforce their safety and efficacy.

 

IMI launches the Call 21 dedicated to CORONAVIRUS:

 

Development of therapeutics and diagnostics combatting coronavirus infections

 

Topic

 

Scope: Considering that this is a newly-identified virus, the scope of this topic remains broad and must address at least one of the following objectives:

  • development of antivirals as well as other types of therapeutics to address a rapid response to the current COVID-19 outbreak;
  • development of therapeutics to address the current and/or future coronavirus outbreaks;
  • development of diagnostics, ensuring rapid evaluation of candidates based on existing technologies;
  • development of fast and reliable tools that go beyond the state of the art for detection of COVID-19 carriers and symptomatic individuals suspected of COVID-19 infection.

 

 

Preventive vaccines are specifically excluded from the scope of the Call.

 

 

For full details of the topic, including the budget breakdown and the General Conditions for the Call for proposals, click on the links above (which take you directly to the relevant page of the Participant Portal) or read the IMI2 - Call 21 Text.

Applicants are also strongly advised to read this questions and answers document. This document is updated regularly - the last update was on 16 March.

 

Indicative budget

  • From EFPIA companies and IMI2 Associated Partners: to be defined based upon selected proposals
  • From the IMI2 JU: EUR 45 000 000

 

Key dates and deadlines

  • Submission start date: 3 March 2020
  • Submission deadline: 31 March 2020

 

More information here : https://www.imi.europa.eu/apply-funding/open-calls/imi2-call-21

 

En poursuivant votre navigation sur notre site, vous acceptez l'utilisation des cookies et la collecte de vos données et informations personnelles par Lyonbiopôle, dans les finalités de mesurer le trafic sur le site Web, de fournir des statistiques et de vous proposer des contenus adaptés à vos centres d’intérets. Pour exercer vos droits d'accès, de rectification, d'opposition, de suppression et de portabilité, conformément au règlement général sur la protection des données (UE n°2016/679), vous etes informés que vous pouvez envoyer votre demande à dpo@lyonbiopole.com. Plus de détails sont disponibles en cliquant ici J'accepte